Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garraway

Showing results (411-420 of 549) with videos related to

Pageof 55
Sort By:
Plos One|September 26, 2013
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequencyMegan C Hanna, Christina Go, Christine Roden, et al.
Cancer Discovery|September 11, 2012
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitorsDalia Ercan, Chunxiao Xu, Masahiko Yanagita, et al.
Blood Advances|December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
BMC Cancer|April 3, 2019
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic diseaseNeil R Parikh, Claudia Huiza, Jill S Patel, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2009
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationH B Salvesen, S L Carter, M Mannelqvist, et al.
The New England Journal of Medicine|October 9, 2014
Response and acquired resistance to everolimus in anaplastic thyroid cancerNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Plos One|June 9, 2017
Systematic genomic and translational efficiency studies of uveal melanomaChelsea Place Johnson, Ivana K Kim, Bita Esmaeli, et al.
Nature Medicine|November 28, 2018
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axisMirja Rotinen, Sungyong You, Julie Yang, et al.
Nature Biotechnology|March 2, 2016
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesChanning Yu, Aristotle M Mannan, Griselda Metta Yvone, et al.
Pageof 55

Showing results (411-420 of 549) with videos related to

Sort By:
Pageof 55
Plos One|September 26, 2013
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequencyMegan C Hanna, Christina Go, Christine Roden, et al.
Cancer Discovery|September 11, 2012
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitorsDalia Ercan, Chunxiao Xu, Masahiko Yanagita, et al.
Blood Advances|December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
BMC Cancer|April 3, 2019
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic diseaseNeil R Parikh, Claudia Huiza, Jill S Patel, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2009
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activationH B Salvesen, S L Carter, M Mannelqvist, et al.
The New England Journal of Medicine|October 9, 2014
Response and acquired resistance to everolimus in anaplastic thyroid cancerNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
Plos One|June 9, 2017
Systematic genomic and translational efficiency studies of uveal melanomaChelsea Place Johnson, Ivana K Kim, Bita Esmaeli, et al.
Nature Medicine|November 28, 2018
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axisMirja Rotinen, Sungyong You, Julie Yang, et al.
Nature Biotechnology|March 2, 2016
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesChanning Yu, Aristotle M Mannan, Griselda Metta Yvone, et al.
Pageof 55